F11 and congenital factor XI deficiency: The great interest in FXI and FXII as potential therapeutic targets for safe and effective antithrombotic strategies comes from the knowledge gained through the study of natural models of the rare hereditary deficiencies of FXI (also called hemophilia C) and FXII.